DK
Machine learning-powered drug discovery and development company building a "pipeline through platform" model. Uses large-scale biological data and ML to discover and develop novel therapeutics, focusing on metabolic disease and neuroscience. Platforms include ChemML for small molecule discovery and TherML for modality-agnostic therapeutic design.
Machine learning-powered drug discovery and development company building a "pipeline through platform" model. Uses large-scale biological data and ML to discover and develop novel therapeutics, focusing on metabolic disease and neuroscience. Platforms include ChemML for small molecule discovery and TherML for modality-agnostic therapeutic design.
Founded in 2018 by Daphne Koller, co-founder of Coursera and former Stanford professor, who saw an opportunity to apply machine learning at scale to transform how drugs are discovered and developed. Headquartered in South San Francisco, the company integrates high-throughput biology, functional genomics, and deep learning.
Insitro acquired CombinAbleAI and launched TherML (Therapeutic Machine Learning), completing its full-stack modality-agnostic drug discovery platform spanning small molecules, oligonucleotides, antibodies, and complex biologics.
Insitro extended its BMS collaboration, providing up to $20M in new funding for one year to design new medicines for a novel ALS target using ChemML, with potential milestones exceeding $2 billion.
Insitro announced collaboration with Eli Lilly to develop ML models predicting key pharmacological properties of small molecules in vivo, representing insitro's third major pharma partnership.
Insitro closed a $400 million Series C round led by SoftBank Vision Fund 2, bringing total funding to over $643 million. The capital accelerates insitro's pipeline-through-platform strategy in metabolic disease and neuroscience.
Insitro announced a strategic research collaboration with Gilead Sciences, applying ML-driven drug discovery approaches to Gilead's therapeutic areas in exchange for funding and milestone payments.
Insitro launched publicly and raised $100M in Series A funding led by Andreessen Horowitz, with Daphne Koller laying out the vision to combine large-scale biology and ML to transform drug discovery economics.
$643M raised total